MedTrace Logo

Effectiveness of Rifabutin for Treatment of Helicobacter Pylori

NCT04652284 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2021-03-10

No results posted yet for this study

Summary

The aim of this study is to determine the effectiveness of rifabutin triple therapy for the treatment of H. pylori infection in the Israeli population. Patients with or without a prior history of H. pylori eradication failure will be randomized to receive one of three possible treatments:

Group 1-amoxicillin 1000mg bd and rifabutin 150 mg bd and esomeprazole 40 mg bd Group 2- amoxicillin 1000mg bd and rifabutin 150 mg d and esomeprazole 40 mg bd Group 3- standard of care

Conditions

  • Helicobacter Infections
  • Resistance Bacterial
  • Gastritis H Pylori

Interventions

DRUG

Rifabutin

150 mg

DRUG

Amoxicillin

1000 mg

DRUG

Esomeprazole

40 mg

DRUG

Clarithromycin

500 mg

DRUG

Tinidazole

500 mg

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • Doron Boltin, MBBS · Rabin Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2023-05-31
Completion
2023-07-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04652284 on ClinicalTrials.gov